Bausch + Lomb launches preservative-free dry eye drops in U.S.

Bausch + Lomb launched Blink Triple Care Preservative Free eye drops in the U.S., with retail availability at Amazon, CVS, Target and Walgreens by the end of June 2026. The product extends dry-eye relief up to 10 hours and targets rising demand tied to screen time and environmental factors. The article is largely a routine product update, but it reinforces the company’s consumer health positioning and ongoing portfolio expansion.

Analysis

This is a small but useful signal that BLCO is trying to reaccelerate consumables growth in a category where brand trust, not formulation novelty, drives repeat purchase. A preservative-free multi-dose format matters because it lowers the friction between “clinical” and “mass retail” dry-eye behavior: that should support higher velocity at Amazon and the big-box pharmacies, while also widening the shelf set against generic store brands that compete mostly on price. The second-order effect is that if the launch gains traction, the mix shift toward branded OTC should improve gross margin quality more than top-line growth alone would imply.

The bigger investment read-through is to BHC, where the market often underprices the value of incremental self-pay consumer launches because they can look immaterial in isolation. If BLCO can keep stacking modest launches across dry-eye, vitamins, and device adjacencies, the story shifts from “levered turnaround” to “portfolio of optionality,” which can compress downside multiples faster than consensus expects. That said, the consumer health channel is promotional and retailer-controlled; any weak initial scan data or heavy couponing would quickly dull the margin benefit within one or two quarters.

For AMZN, CVS, and TGT, the near-term impact is more about shelf fill than earnings. These retailers benefit if the product category continues to expand, but the incremental gross profit pool is small, so the trade is really about category traffic and attachment rather than direct dollar contribution. The contrarian risk is that dry-eye is a crowded, low-switching-cost aisle: if this launch mainly cannibalizes existing Blink SKUs or private label, the net share gain could be close to zero even if reported distribution looks strong.

Key Decisions for Investors

• Long BLCO vs. a basket of low-quality consumer health peers on a 3-6 month horizon; thesis is that branded OTC launches will show better-through-rate than expected and support a rerating from turn-around to durable consumables story.
• Add to BHC only on confirmation of sell-through data, not headline distribution; use a 1-2 quarter window and treat weak retailer velocity as a reason to exit quickly because promotional support can erase margin gains.